Buradasınız

Anasayfa » Content

Kanser Kemoterapisi ve Böbrek

Cancer Chemotherapy and Kidney

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The nephrotoxicity of cancer chemotherapy varies from mild serum creatinine level elevation to end stage kidney failure depending on the type and dosage of the drug. Saline-based hydration confer protection against chemotherapy-induced nephrotoxicity. The mortality and morbidity rates can be decreased by preventing the chemotherapy-induced nephrotoxicity. In this compilation, we aimed evaluating the mechanisms of chemotherapy induced nephrotoxicity of the most frequently observed cancer drugs and kidney disorder depending on chemotherapy.
Bookmark/Search this post with
Abstract (Original Language): 
Kanser ilaçlarının tipine ve dozuna bağlı olarak serum kreatininin hafif yükselmesinden son dönem böbrek yetmezliğine kadar ciddi boyutta böbrek bozukluğu görülebilmektedir. Kemoterapi öncesi sağlanacak yeterli hidrasyonla nefrotoksisite büyük ölçüde önlenebilir. Kemoterapiye bağlı nefrotoksisitenin önlenmesi ile hastaların mortalite ve morbidite oranı azaltılabilir. Bu derlemede kemoterapiye bağlı böbrek bozukluğunu ve nefrotoksisitesi en sık gözlenen kanser ilaçlarının nefrotoksik etki mekanizmalarını değerlendirmeyi amaçladık.
FULL TEXT (PDF): 
PDF icon arastirmax-kanser-kemoterapisi-bobrek.pdf
  • 1
63-68
  • Turkish

REFERENCES

References: 

1. Kintzel PE. Anticancer drug-induced kidney disorders. Incidence, prevention and management. Drug Safety 2001; 24:19-38.
2. Boogaard PJ, Nagelkerke JF, Mulder GJ: Renal proximal tubular cells in suspension or in primary culture as in vitro models to study nephrotoxicity. Chem. Biol. Interact 1990; 76: 281-291.
3. Fillastre JP, Godin M. Drug-induced nephropathies. In Davison AM, Cameron JS, Grünfeld JP, et al. Oxford Textbook of Clinical Nephrology. New York: Oxford University Press 1998; 2645-2657.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
5. Meister LA, Meadows AT. Late effects of childhood cancer therapy. Curr Probl Prediatr 1993; 23,102-131.
6. Ikarashı Y, Kakıhara Y, Imaı C et al. Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children. Pediatrics International 2004; 46: 570-575.
7. Fels LM, Bokemeyer C, van Rhee J. Evaluation of late nephrotoxicity in long-term survivors of Hodgkin’s disease. Oncology ,1996; 53:73-78.
8. Skinner R, Pearson AD, English MW. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998; 77: 1677-1682.
9. Seiler MW, Rennke HG, Venatachalam MA, Cotran RS. Pathogenesis of polycation-induced alteration’s ‘fusion’ of glomerular epithelium. Lab. Invest 1977; 36:48-61.
10. Andrews P. Morphological alterations of the glomerular (visceral) epithelium in response to pathological and experimental situations. J Electron Microsc Tech 1988; 9: 115-124.
11. Watanabe A, Kakihara T, Hara M et al. Morphological differences between glomerular epithelial cells (GEC) excreted during chemotherapy with antineoplastic drugs and GEC excreted in renal diseases. Pediatr. Int 2001; 43: 587-591.
12. Fajardo LF, Eltringham JR, Stewart JR, Klauber MR. Adriamycin nephrotoxicity. Lab. Invest 1980; 43: 242-253.
13. Harmon WE, Cohen HJ, Schneeberger EE, Grupe WE. Chronic renal failure in children treated with methyl CCNU. NEJM 1979; 300: 1200-1203.
14. Alpers C Cotran RS. Neoplasia and Glomerular injury. Kidney International 1986; 30: 465-473.
15. Dabbs DJ, Striker LMM, Mignon F, Striker G. Glomeruler lesions in lymphomas and leukemias. Am J Med 1986; 80:63-70.
16. Glassock RJ, Massry SG. Neoplasia Textbook of Nephrology. Glassock RJ, Massry SG(eds). Williams and Wilkins, Baltimore 1996: 1117-1123.
17. Loehrer PJ, Einhorn LH: Drugs five years later Cisplatin. Ann Intern Med 1984; 100: 704-713.
18. Emmerson BT. Toxic Nephrophaty. Oxford Textbook of Medicine 3rd Ed. Vol.3 (Eds), Weatherall, DJ, Ledingham, JGG, Warrell DA. Oxford, New York: Tokyo, Oxford University Pres, 1996: 3258-3267.
19. Bertram G: Basic Clinical Pharmacology 9 ed. 2001: 1285-1300.
20. Links M, Lewis C: Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999; 57: 293-308.
21. Leonard BJ, Eccleston E, Jones D, Todd P, Walpoles A: Antileukemic and nephrotoxic properties of platinum compounds. Nature 1971; 234:43-45.
22. McEvoy GK, editor, Bethesda, Maryland: AHFS 2004 Drug Information. American Society of Health-System. Pharmacists, 2004: 929-952.
23. Levi J, Jacobs C, Kalman SM: Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 1980; 213:545-550.
24. el Daly ES. Protective effect of cysteine and vitamin E, Crocus stativus and Nigella sativa extracts on cisplatin-induced toxicity in rats. J Pharm Belg 1998; 53: 87-95.
25. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993; 23: 1519-1527.
26. Dentino M, Luft FC, Moo N Y et al. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41:1247-1251.
27. Loehrer PJ, Einhorn LH. Drugs five years later Cisplatin. Ann Intern Med 1984; 100:704-713.
28. Offerman, JJG. Acute effects of cis-diammine dichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 1984; 12: 36-38.
29. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90: 929-931.
30. Go R, Adjel A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422.
31. Goren MP, Wright RK, Horowitz ME, Pratt CB: Ifosphamide-induced subclinical nephrotoxicity despite MESNA. Cancer Treat Rep 1987; 71: 127-130.
32. Repchinsky C. Compendium of Pharmaceuticals and Specialties, 2004: 1610-1613.
33. Miller LJ, Chandler SW, Ippoliti CM. Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins. Ann Pharmacother 1994; 28: 590-594.
34. West NJ. Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 1997; 17: 696-706.
35. Shepherd JD, Pringle LE, Barnett MJ et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9: 2016-2020.
36. Erkurt MA, Aydogdu I, Kuku I, Kaya E, Ozhan O. Anticancer Drug Induced Glomerular Dysfunction. W J Med Sci 2008; 3: 5-9.
37. Go R, Adjel A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422
38. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. NEJM 2001;344:1997-2008.
39. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222-32.
40. Aronoff GR, Bennett WM, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing guidelines for adults and children. 5th ed. Philadelphia, Pennsylvania: American College of Physicians; 2007. p. 101.
41. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy. 3rd ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001. p. 373-414.
42. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40.
43. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clinical Pharmacology & Therapeutics 2000;68:556-67.
44. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc. 2004;36:229-233

Thank you for copying data from http://www.arastirmax.com